Open | 1.19 |
Previous Close | 1.25 |
Day Range | 1.17 - 1.24 |
52-Week Range | 1.14 - 6.99 |
All-Time High | 1,590.00 |
Avg. Volume (50-day) | 85,577.72 |
EPS (TTM) | -9.68 |
Next Earnings Date | 2024-11-07 |
Last Earnings Date | 2024-08-09 |
Forward Annual Dividend (Yield) | - |
Trailing Annual Dividend (Yield) | - |
Options | No |
P/E Ratio | -0.13 |
PEG Ratio | - |
Price to Book | 1.89 |
Price to Cash Flow | - |
Price to Free Cash Flow | - |
Total Sales (TTM) | - |
Revenue per Share (TTM) | - |
Shares Outstanding | 2.109 M |
Share Float (%) | 2.07 M |
% Held by Institutions | 7.07 |
Dividends Per Share (TTM) | - |
Ex-Dividend Date | - |
+/- EMA(20) | 1.4 (-16.07%) |
+/- SMA(50) | 1.65 (-28.79%) |
+/- SMA(200) | 2.39 (-50.84%) |
5-Day Perf. | -16.67% |
1-Month Perf. | -21.14% |
3-Month Perf. | -43.51% |
6-Month Perf. | -45.35% |
YTD Perf. | -42.12% |
1-Year Perf. | -82.9% |
RSI(14) | 30.58 |
ATR(14) | 0.15 |
ADX(14) | 24.14 |
Beta (5Y) | - |
Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. It also develops TH104, which is known to suppress chronic, debilitating pruritus or uncontrollable itching in PBC, a rare and orphan liver disease with no known cure. The company was founded on March 28, 2017 and is headquartered in Bridgewater, NJ.
THAR has triggered the following predefined scans:
P&F Double Bottom Breakdown |
As a StockCharts Member, you can create your own unique alerts with the technical criteria that matters most to you. Stay ahead of important moves and never miss a thing in the markets.
As a StockCharts Member, you can save the charts you're watching to your own account with ChartLists. Accessible from any device, you can organize, review and analyze your charts on-the-go, anytime, anywhere.